Copyright held by the owner/author(s).
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license. This work is licensed under a Creative Commons Attribution 4.0 International ...
Merck announced today that pembrolizumab (Keytruda) injected subcutaneously is not inferior to intravenous (IV) dosing, currently the drug’s only approved route of administration. In the phase III ...
Major Finding: A dual function supracluster was engineered to increase radiosensitivity and antitumor immunity. Concept: Gold supraclusters carrying siRNA against LGALS1 (galectin-1) reshaped the ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International ...
Search for other works by this author on: ...
1Fred Hutchinson Cancer Center, Seattle, WA.
Bristol Myers Squibb (BMS) faces a $6.7 billion lawsuit alleging that the company purposely delayed approval of Celgene-developed drugs to avoid paying Celgene shareholders owning contingent value ...
Aging is the most important and well-recognized risk factor for cancer. Aging leads to systemic decline of physical fitness, significantly changing the macroenvironment from the early tumor initiation ...
Copyright held by the owner/author(s). This open access article is distributed under the Creative Commons Attribution 4.0 International (CC BY 4.0) license ...
Clin Cancer Res (2024) 30 (21_Supplement): A045.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback